Anne Healy, MD
Internal Medicine · New Bern, NCNPI 1598949935
Payments from drug & device makers
Across 302 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Lilly USA, LLC$543
- Novo Nordisk$540
- AstraZeneca$467
- GSK$382
- AbbVie$274
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,734100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 88 | $1,189 |
| Lilly USA, LLC | 35 | $543 |
| Novo Nordisk | 31 | $540 |
| AstraZeneca | 22 | $467 |
| GSK | 19 | $382 |
| AbbVie(2 entities) | 18 | $274 |
| Boehringer Ingelheim | 17 | $253 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $206 |
| Pfizer | 13 | $180 |
| Astellas Pharma US Inc | 7 | $106 |
| Dexcom, Inc. | 5 | $76 |
| Daiichi Sankyo Inc. | 5 | $73 |
| Sumitomo Pharma America, Inc. | 3 | $49 |
| Merck | 3 | $43 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Mylan Specialty L.p. | 3 | $37 |
| Radius Health, Inc. | 2 | $33 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Grifols USA, LLC | 1 | $25 |
| Abbott | 1 | $22 |
| Dermira, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Phadia US Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$118
- TRELEGY ELLIPTA$110
How this compares
$4,734 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 82 | $59,406 |
| EliquisApixaban | 68 | $48,192 |
| MounjaroTirzepatide | 25 | $35,923 |
| OzempicSemaglutide | 19 | $28,748 |
| FarxigaDapagliflozin Propanediol | 46 | $26,499 |
| Repatha SureclickEvolocumab | 35 | $18,726 |
| MyrbetriqMirabegron | 17 | $13,257 |
| Repatha SyringeEvolocumab | 15 | $9,888 |
| SynthroidLevothyroxine Sodium | 60 | $5,060 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 19 | $4,266 |
| Potassium Chloride | 181 | $3,471 |
| Atorvastatin Calcium | 325 | $2,881 |
| Levothyroxine Sodium | 205 | $2,473 |
| Metoprolol Succinate | 138 | $2,107 |
| Rosuvastatin Calcium | 187 | $2,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $253 | $59,40682 claims |
| PfizerEliquis | $180 | $48,19268 claims |
| Lilly USA, LLCMounjaro | $543 | $35,92325 claims |
| Novo NordiskOzempic | $540 | $28,74819 claims |
| AstraZenecaFarxiga | $467 | $26,49946 claims |
| Astellas Pharma US IncMyrbetriq | $106 | $13,25717 claims |
| AbbVieSynthroid | $274 | $5,06060 claims |
| GSKShingrix | $382 | $4,26619 claims |
| Upsher-smith Laboratories LLCTopiramate | $15 | $63518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in New Bern
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.